Surveillance for human immunodeficiency virus type 1 group O infections in the United States

C. P. Pau; D. J. Hu; C. Spruill; C. Schable; E. Lackritz; M. Kai; J. R. George; M. A. Rayfield; T. J. Dondero; A. E. Williams; M. P. Busch; A. E. Brown; F. E. Mccutchan; G. Schochetman

doi:10.1046/j.1537-2995.1996.36596282582.x

Surveillance for human immunodeficiency virus type 1 group O infections in the United States

C. P. Pau, D. J. Hu, C. Spruill, C. Schable, E. Lackritz, M. Kai, J. R. George, M. A. Rayfield, T. J. Dondero, A. E. Williams, M. P. Busch, A. E. Brown, F. E. Mccutchan, G. Schochetman

Research output: Contribution to journal › Article › peer-review

25 Scopus citations

Abstract

Background: Reports that the human immunodeficiency virus type 1 (HIV- 1) group O variants are not reliably detected by some commercial diagnostic tests have raised concerns about the sensitivity of existing screening tests, especially with regard to blood safety. Although it is unlikely that these divergent strains are prevalent in North America, systematic, continuous surveillance is needed to monitor the potential spread of HIV variants into that region. Study Design and Methods: Stored serum samples (n = 1072) from both high- and low-risk population groups at several sites in the United States and Puerto Rico were tested by peptide enzyme immunoassays specific for the prototypic HIV-1 group O strains, MVP5180 and ANT70. Results: None of the 1072 samples examined had peptide reactivity that was consistent with HIV-1 group O infection. Conclusion: While no evidence of specific HIV-1 group O (MVP5180 or ANT70) infection was found in this study, the sensitivity of current tests has not been fully evaluated against the wide range of genetic variation of HIV. Therefore, it is important to continue active surveillance for HIV-1 and HIV type 2 strains, to characterize any divergent strains, and to judiciously modify tests to correct for any deficiencies in sensitivity.

Original language	English (US)
Pages (from-to)	398-400
Number of pages	3
Journal	Transfusion
Volume	36
Issue number	5
DOIs	https://doi.org/10.1046/j.1537-2995.1996.36596282582.x
State	Published - May 1996
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Publisher link

10.1046/j.1537-2995.1996.36596282582.x

Find It

Find It at U of M Libraries

Cite this

Pau, C. P., Hu, D. J., Spruill, C., Schable, C., Lackritz, E., Kai, M., George, J. R., Rayfield, M. A., Dondero, T. J., Williams, A. E., Busch, M. P., Brown, A. E., Mccutchan, F. E., & Schochetman, G. (1996). Surveillance for human immunodeficiency virus type 1 group O infections in the United States. Transfusion, 36(5), 398-400. https://doi.org/10.1046/j.1537-2995.1996.36596282582.x

@article{820ab4d3ac2944ee8e16429b4e2af029,

title = "Surveillance for human immunodeficiency virus type 1 group O infections in the United States",

abstract = "Background: Reports that the human immunodeficiency virus type 1 (HIV- 1) group O variants are not reliably detected by some commercial diagnostic tests have raised concerns about the sensitivity of existing screening tests, especially with regard to blood safety. Although it is unlikely that these divergent strains are prevalent in North America, systematic, continuous surveillance is needed to monitor the potential spread of HIV variants into that region. Study Design and Methods: Stored serum samples (n = 1072) from both high- and low-risk population groups at several sites in the United States and Puerto Rico were tested by peptide enzyme immunoassays specific for the prototypic HIV-1 group O strains, MVP5180 and ANT70. Results: None of the 1072 samples examined had peptide reactivity that was consistent with HIV-1 group O infection. Conclusion: While no evidence of specific HIV-1 group O (MVP5180 or ANT70) infection was found in this study, the sensitivity of current tests has not been fully evaluated against the wide range of genetic variation of HIV. Therefore, it is important to continue active surveillance for HIV-1 and HIV type 2 strains, to characterize any divergent strains, and to judiciously modify tests to correct for any deficiencies in sensitivity.",

author = "Pau, {C. P.} and Hu, {D. J.} and C. Spruill and C. Schable and E. Lackritz and M. Kai and George, {J. R.} and Rayfield, {M. A.} and Dondero, {T. J.} and Williams, {A. E.} and Busch, {M. P.} and Brown, {A. E.} and Mccutchan, {F. E.} and G. Schochetman",

year = "1996",

month = may,

doi = "10.1046/j.1537-2995.1996.36596282582.x",

language = "English (US)",

volume = "36",

pages = "398--400",

journal = "Transfusion",

issn = "0041-1132",

publisher = "John Wiley and Sons Inc.",

number = "5",

}

TY - JOUR

T1 - Surveillance for human immunodeficiency virus type 1 group O infections in the United States

AU - Pau, C. P.

AU - Hu, D. J.

AU - Spruill, C.

AU - Schable, C.

AU - Lackritz, E.

AU - Kai, M.

AU - George, J. R.

AU - Rayfield, M. A.

AU - Dondero, T. J.

AU - Williams, A. E.

AU - Busch, M. P.

AU - Brown, A. E.

AU - Mccutchan, F. E.

AU - Schochetman, G.

PY - 1996/5

Y1 - 1996/5

N2 - Background: Reports that the human immunodeficiency virus type 1 (HIV- 1) group O variants are not reliably detected by some commercial diagnostic tests have raised concerns about the sensitivity of existing screening tests, especially with regard to blood safety. Although it is unlikely that these divergent strains are prevalent in North America, systematic, continuous surveillance is needed to monitor the potential spread of HIV variants into that region. Study Design and Methods: Stored serum samples (n = 1072) from both high- and low-risk population groups at several sites in the United States and Puerto Rico were tested by peptide enzyme immunoassays specific for the prototypic HIV-1 group O strains, MVP5180 and ANT70. Results: None of the 1072 samples examined had peptide reactivity that was consistent with HIV-1 group O infection. Conclusion: While no evidence of specific HIV-1 group O (MVP5180 or ANT70) infection was found in this study, the sensitivity of current tests has not been fully evaluated against the wide range of genetic variation of HIV. Therefore, it is important to continue active surveillance for HIV-1 and HIV type 2 strains, to characterize any divergent strains, and to judiciously modify tests to correct for any deficiencies in sensitivity.

AB - Background: Reports that the human immunodeficiency virus type 1 (HIV- 1) group O variants are not reliably detected by some commercial diagnostic tests have raised concerns about the sensitivity of existing screening tests, especially with regard to blood safety. Although it is unlikely that these divergent strains are prevalent in North America, systematic, continuous surveillance is needed to monitor the potential spread of HIV variants into that region. Study Design and Methods: Stored serum samples (n = 1072) from both high- and low-risk population groups at several sites in the United States and Puerto Rico were tested by peptide enzyme immunoassays specific for the prototypic HIV-1 group O strains, MVP5180 and ANT70. Results: None of the 1072 samples examined had peptide reactivity that was consistent with HIV-1 group O infection. Conclusion: While no evidence of specific HIV-1 group O (MVP5180 or ANT70) infection was found in this study, the sensitivity of current tests has not been fully evaluated against the wide range of genetic variation of HIV. Therefore, it is important to continue active surveillance for HIV-1 and HIV type 2 strains, to characterize any divergent strains, and to judiciously modify tests to correct for any deficiencies in sensitivity.

UR - http://www.scopus.com/inward/record.url?scp=8944229196&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=8944229196&partnerID=8YFLogxK

U2 - 10.1046/j.1537-2995.1996.36596282582.x

DO - 10.1046/j.1537-2995.1996.36596282582.x

M3 - Article

AN - SCOPUS:8944229196

SN - 0041-1132

VL - 36

SP - 398

EP - 400

JO - Transfusion

JF - Transfusion

IS - 5

ER -

Surveillance for human immunodeficiency virus type 1 group O infections in the United States

Abstract

UN SDGs

Publisher link

Find It

Other files and links

Fingerprint

Cite this